Study of C1 Herbal oil healing properties in skin wounds

Controlled Clinical Trial to assess the effectiveness of topical application of C1 herbal oil on superficial external wounds and split thickness skin graft donor sites for surgical wound healing

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010150

Enrollment

Registered

2017-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having Superficial external wounds and Split thickness skin graft (STSG) donor sites

Interventions

Intervention1: C1 herbal Oil: C1 herbal oil is applied as a thin Layer in form of Gel topically on the STSG donor site on the 1st day and results are assessed for next 10 to 21 days Intervention2: C1

Eligibility

Inclusion criteria

Inclusion criteria: Patients with wounds requiring STSG cover

Exclusion criteria

Exclusion criteria: 1. Known allergy/hypersensitivity to any of the components of the dressing 2. Fracture/DVT of lower extremity 3. A skin disorder that is chronic or currently active 4. Polytrauma patients 5. Wound at the surgical site prior to surgery 6. Neurological deficit at wound site (Hemiplegia etc.) 7. Haemoglobin level 8. Serum Albumin 9. Subjects who, in the opinion of investigator, may not complete the study for any reason 10. Hepatic failure, renal failure, coagulopathy, known cases of Diabetes mellitus 11. Immunocompromised patients such as with Acquired immunodeficiency syndrome or receiving systemic immune suppression 12. Patients who have psychiatric disorders or physical disabilities that hinders the study 13. Pregnancy or Lactation 14. Patient has history of poor wound healing, history of smoking/drug/alcohol abuse 15. Poor prognosis patients unlikely to survive the trial period 16. Patients where a reference wound cannot be treated in isolation from other wounds

Design outcomes

Primary

Measure	Time frame
1. Time to complete re-epithelisation 2. Incidence of Wound infection 3. Incidence of Adverse Reactions including allergic contact dermatitisTimepoint: 4 weeks	—

Secondary

Measure	Time frame
1. Dressing Adherence Score 2. Pain during dressing changes 3. Any systemic effects after treatment Incidence of BlisteringTimepoint: 10 days 2 weeks 6 days	—

Countries

India

Contacts

Public ContactDr Maneesh Singhal

All India Institute of Medical Sciences

drmaneesh@gmail.com26594430

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 12, 2026